• Observe Medical posted first-half 2026 revenue of NOK 14.4 million, up 27.4% year over year.
• Reported EBITDA swung to NOK 7.9 million, including a NOK 18 million non-cash gain from Biim Ultrasound deconsolidation.
• Adjusted EBITDA was a loss of NOK 8.3 million, excluding the gain and NOK 2 million of non-recurring restructuring costs.
• Net profit was NOK 5.6 million, while gross margin improved 3.3 percentage points to 29.5%.
• CEO Jørgen Mann said distribution is expanding; UnoSafeCoat clinical data was accepted for publication, supporting Safeti Max and Sippi.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Observe Medical ASA published the original content used to generate this news brief via Cision (Ref. ID: 20260824:BIT:1324:0) on August 25, 2026, and is solely responsible for the information contained therein.